Skip to content

Xencor XNCR Stock-Based Comp

Stock-Based Comp at other companies

Amgen logo
AmgenAMGN
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
Summit Therapeutics logo
Summit TherapeuticsSMMT
XOMA Corporation logo
XOMA CorporationXOMA
Zymeworks logo
ZymeworksZYME

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's stock-based comp?
Xencor (XNCR) reported stock-based comp of $9.56M in Q1 2026.
How has Xencor's stock-based comp changed year-over-year?
Xencor's stock-based comp decreased by 21.7% year-over-year, from $12.21M to $9.56M.
What is the long-term trend for Xencor's stock-based comp?
Over 4 years (2021 to 2025), Xencor's stock-based comp has grown at a 4.0% compound annual growth rate (CAGR), from $36.98M to $43.23M.